Compare · BDX vs SONX
BDX vs SONX
Side-by-side comparison of Becton Dickinson and Company (BDX) and Sonendo Inc. (SONX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SONX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 268.5x SONX ($192.5M).
- BDX has hit the wire 10 times in the past 4 weeks while SONX has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 6 for SONX).
- Company
- Becton Dickinson and Company
- Sonendo Inc.
- Price
- $190.44+0.34%
- $0.23-5.15%
- Market cap
- $51.69B
- $192.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 6
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Sonendo Inc.
Sonendo, Inc. develops, manufactures, and sells devices for root canal therapy in the United States and Canada. It offers GentleWave, a device to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of ethylenediaminetetraacetic acid used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software. The company was formerly known as Dentatek Corporation and changed its name to Sonendo, Inc. in March 2011. Sonendo, Inc. was incorporated in 2006 and is based in Laguna Hills, California.
Latest BDX
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
Latest SONX
- Amendment: SEC Form SCHEDULE 13G/A filed by Sonendo Inc.
- Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer
- Sonendo, Inc. Reports Second Quarter 2025 Financial Results and Reaffirms Financial Guidance
- Sonendo, Inc. Reports First Quarter 2025 Financial Results and Issues Financial Guidance
- SEC Form D filed by Sonendo Inc.
- Sonendo, Inc. Announces $5.0 Million Private Placement
- SEC Form 10-K filed by Sonendo Inc.
- Sonendo Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
- SEC Form EFFECT filed by Sonendo Inc.
- SEC Form EFFECT filed by Sonendo Inc.